Cybrexa Therapeutics reports that the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate.
The open-label, multicenter study will evaluate CBX-12 in patients with advanced or metastatic refractory solid tumors. The primary objectives of Phase 1 are to determine the safety and tolerability, maximum tolerated doses and dose limiting toxicities of CBX-12, and to establish the recommended Phase 2 dose of CBX-12. Two Phase 2 expansion cohorts will evaluate patients with platinum-resistant ovarian cancer and small cell lung cancer.